NCT05228821撤回4 期
An Open Label, Single Arm, Multicenter Study to Evaluate the Effect of Voxelotor on Cerebral Blood Flow and Neurocognitive Function in Adolescents and Adults With Sickle Cell Disease
适应症
干预措施
试验速览
- 阶段
- 4 期
- 状态
- 撤回
- 发起方
- Pfizer
- 试验地点
- 2
- 主要终点
- Change in CBF
研究概览
简要总结
This is an open label, single arm multicenter trial to evaluate the effect of voxelotor treatment on cerebral blood flow (CBF) and neurocognitive function in adolescent and young adult participants (12-30 years of age) with sickle cell disease (SCD).
详细描述
Eligible participants will receive daily treatment with 1500 mg voxelotor for 24 weeks. During screening, at 12 and 24 weeks, participants will undergo an MRI for evaluation of cerebral blood flow and oxygen extraction fraction as well as NIH toolbox testing for evaluation of executive function, processing speed, and nonexecutive function.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 12 Years 至 30 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female participants with confirmed diagnosis of SCD with HbSS or Hbβ0 thalassemia genotype. Documentation of SCD genotype is required and may be based on documented history of laboratory testing or confirmed by laboratory testing during Screening.
- •Aged 12 to 30 years.
- •Screening Hb level ≥ 5.5 and ≤ 10.5 g/dL.
- •Must meet site-specific compliance requirements for a diagnostic MRI scan.
- •Able to answer NIH Toolbox Module questions in English
- •If participant is receiving hydroxyurea (HU) they must have been on a stable dose for at least 90 days prior to signing the ICF/AF, with no dose modifications or initiation of HU planned or anticipated by the Investigator.
- •If participant is receiving erythropoiesis-stimulating agents (ESAs) they must have been on a stable dose for at least 12 weeks before enrollment with no dose modifications planned or anticipated by the Investigator.
- •Participants, who if female and of child-bearing potential, agree to use highly effective methods of contraception from study start to 30 days after the last dose of study drug and who if male, agree to use barrier methods of contraception and refrain from donating sperm from study start to 30 days after the last dose of study drug.
- •Females of child-bearing potential must have a negative pregnancy test before the administration of study drug.
- •Written informed consent (≥ 18 years) or parental/guardian consent and participant assent (≥ 12-17 years) per Institutional Review Board (IRB) policy and requirements, consistent with ICH guidelines.
- •Capable of complying with the requirements and restrictions in the protocol, and willing to participate in the study.
排除标准
- •History of overt stroke including hemorrhagic stroke, transient ischemic attacks, or spinal cord injury.
- •Grade 4 vasculopathy defined as moderate stenosis (50% to 69%) in more than 2 major cerebral arteries or severe stenosis (> 70%) in any major cerebral artery.
- •Non-MRI compatible metal hardware and/or metal braces.
- •Congenital brain malformation, previously diagnosed severe developmental disability (eg autism and/or intelligence quotient [IQ] <60, and/or severe attention deficit hyperactivity disorder [ADHD]), or impairment that would prevent the use of a computer tablet.
- •Participant is taking or has received voxelotor (Oxbryta®) within 90 days prior to the Screening Visit.
- •Participant is taking or has received crizanlizumab (Adakveo®) within 90 days prior to the Screening Visit.
- •Vaso-occlusive event requiring intravenous opioids within 28 days prior to Day
- •Red blood cell (RBC) transfusion within 3 months before initiation of study drug or receives scheduled RBC transfusion therapy (also termed chronic, prophylactic, or preventive transfusion).
- •Surgery within 8 weeks before Day 1 or planned elective surgery during the study.
- •Anemia due to bone marrow failure (eg, myelodysplasia).
- •Absolute reticulocyte count (ARC) < 100 × 10^9/L.
- •Screening alanine aminotransferase or aspartate aminotransferase > 4× upper limit of normal (ULN).
- •Severe renal dysfunction (estimated glomerular filtration rate [eGFR] <45 mL/min/1.73 m^2) or on chronic dialysis.
- •Clinically significant bacterial, fungal, parasitic, or viral infection which requires therapy
- •Acute bacterial infection requiring antibiotic use should delay Screening/enrollment until the course of antibiotic therapy has been completed.
- •Known active hepatitis A, B, or C or are known to be human immunodeficiency virus (HIV) positive.
- •Symptomatic coronavirus disease of 2019 (COVID-19) infection.
- •Females who are breast-feeding or pregnant.
- •History of hematopoietic stem cell transplant or gene therapy.
- •Participants taking concomitant medications such as sensitive CYP3A4 substrates with a narrow therapeutic range, or strong CYP3A4 inducers.
- •Participated in another clinical trial of an investigational product (or medical device) within 30 days or 5 half-lives of date of informed consent, whichever is longer, or is currently participating in another trial of an investigational product (or medical device).
- •Medical, psychological, or behavioral condition that, in the opinion of the Investigator, would confound or interfere with evaluation of safety and/or efficacy of the study drug, prevent compliance with the study protocol; preclude informed consent; or render the participant unable/unlikely to comply with the study procedures (particularly the MRI scan).
研究组 & 干预措施
Active Drug
Experimental
Generic Name: Voxelotor Dosage Form: tablet Dosage: 1500mg Frequency: QD Duration: 24 weeks
干预措施: Voxelotor Oral Tablet (Drug)
结局指标
主要结局
Change in CBF
时间窗: Baseline to Week 24
Change from Baseline in CBF through Week 24 measured by magnetic resonance imaging (MRI) using pseudo-continuous arterial spin labeling (pCASL).
次要结局
- Change in processing speed(Baseline to Week 24)
- Change in nonexecutive functioning(Baseline to Week 24)
- Change in executive functioning.(Baseline to Week 24)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
Voxelotor CYP and Transporter Cocktail Interaction StudySickle Cell DiseaseNCT05981365Pfizer44
已完成
3 期
Caplacizumab and Immunosuppressive Therapy Without Firstline Therapeutic Plasma Exchange in Adults With Immune-mediated Thrombotic Thrombocytopenic PurpuraThrombotic Thrombocytopenic PurpuraNCT05468320Sanofi51
已完成
2 期
A Study of Peginterferon Alfa-2a With or Without Ribavirin in Participants With Chronic Hepatitis D (CHD)Hepatitis D, ChronicNCT02731131Hoffmann-La Roche12
尚未招募
1 期
Surufatinib Combined With Tislelizumab in the Second-line and Further Treatment of Triple-negative Breast CancerMetastatic Triple-negative Breast CancerNCT05746728Huihua Xiong45
已完成
1 期
Efficacy and Safety of PI3K Inhibitors in Relapsed/Refractory Large Granular T Lymphocytic LeukemiaRelapsed/Refractory Large Granular T Lymphocytic LeukemiaNCT05676710Institute of Hematology & Blood Diseases Hospital, China8